AbbVie (ABBV) reports strong Q4 earnings and raises 2026 profit outlook to $14.37-$14.57 per share, beating Wall Street estimates, though investors worry about Humira decline and aesthetics challenges.
Merck has walked away from negotiations to acquire Revolution Medicines after failing to agree on price for the promising cancer drug developer valued around $30 billion.
AbbVie denies reports of buying Revolution Medicines after Wall Street Journal claimed advanced talks.
LENZ Therapeutics shares dropped 27% following reports of a retinal tear associated with VIZZ presbyopia treatment, raising investor safety concerns despite company reassurances.
Ironwood shares climb after AbbVie reports strong Q3 Linzess sales of $315M, surpassing estimates and boosting investor confidence.
H.C. Wainwright sets $26 price target for Zymeworks after Phase 1 data shows ZW191 cancer drug outperforms FDA-approved competitor with 44% response rate.
